Recently, Genalive, a joint venture between BGI Almanahil Health for Medical Services (a wholly owned subsidiary of BGI Genomics) and Tibbiyah Holding (a wholly owned subsidiary of Saudi Al Faisaliah Group), opened its independent clinical laboratory.

Genalive is a laboratory with advanced bioinformatics processing capabilities, covering approximately 4,000 square meters with a large data center, and Genalive CEO Saeed Al-Amoudi said, "Through this joint venture, BGI Genomics and Tibbiyah can work together to advance genetic research and precision medicine to contribute to the development of the Saudi healthcare industry and ultimately improve patient outcomes."

In the future, through Genalive, BGI Genomics will bring Chinese technologies such as non-invasive prenatal genetic testing, single gene genetic disease carrier testing, neonatal disease testing, genetic tumor testing and infectious disease testing to the Middle East market. In addition, it will help the development of Saudi Arabia's precision medicine and public health services, escort the realization of Saudi Arabia's "Vision 2030" and contribute to the "Belt and Road".